Structure-affinity relationships of indole-based melatonin analogs

NeuroSignals

Volumn 8, Issue 1-2, 1999, Pages 15-23

  Spadoni, Gilberto ^a   Mor, Marco ^b   Tarzia, Giorgio ^a  

^a UNIVERSITY OF URBINO   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

Binding affinity; Melatonergic ligands; Melatonin analogs

Indexed keywords

HORMONE ANALOG; INDOLE; LIGAND; MELATONIN; MELATONIN RECEPTOR;

ANIMAL TISSUE; BINDING AFFINITY; CONFORMATION; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW;

ANIMALS; BINDING SITES; BRAIN; DRUG DESIGN; HUMANS; INDOLES; KINETICS; LIGANDS; MELATONIN; MODELS, MOLECULAR; MOLECULAR CONFORMATION; RECEPTORS, CELL SURFACE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, MELATONIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033002220     PISSN: 1424862X     EISSN: 14248638     Source Type: Journal    
DOI: 10.1159/000014564     Document Type: Article

References (36)

1. Reiter RJ: Pineal melatonin: Cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991;12:151-180.
2. Arendt J, Deacon S: Treatment of circadian rhythm disorders-Melatonin. Chronobiol Int 1997; 14:185-204.
3. Zhdanova IV, Wurtman RJ, Lynch HJ, Ives JR, Dollins AB, Morabito C, Matheson JK, Schomer DL: Sleep-inducing effects of low doses of melatonin ingested in the evening. Clin Pharmacol Ther (St Louis) 1995;57:552-558.
4. Arendt J, Skene DJ, Middleton B, Lockley SW, Deacon S: Efficacy of melatonin treatment in jet lag, shift work and blindness. J Biol Rhythms 1997;12:604-617.
5. Oldani A, Ferini-Strambi L, Zuc-coni M, Stankov B, Fraschini F, Smirne S: Melatonin and delayed sleep phase syndrome: Ambulatory polygraphic evaluation. Neuroreport 1994;6:132-134.
6. Champney TH, Hanneman WH, Legare ME, Appel K: Acute and chronic effects of melatonin as an anticonvulsivant in male gerbils. J Pineal Res 1996;20:79-83.
7. Pappola MA, Sos M, Omar RA, Bick RJ, Hickson-Bick DLM, Reiter RJ, Efthimiopoulos S, Robakis NK: Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer peptide. J Neurosci 1997;17: 1683-1690.
8. Maestroni GJM: The immunoneu-roendocrine role of melatonin. J Pineal Res 1993;14:1-10.
9. Blask DE, Wilson ST, Zalatan F: Physiological melatonin inhibition of human breast cancer cell growth in vitro: Evidence for a glutathione-mediated pathway. Cancer Res 1997;57:1909-1914.
10. Reiter RJ: The indoleamine melatonin as a free radical scavenger, electron donor, and antioxidant: In vitro and in vivo studies. Adv Exp Med Biol 1996;398:307-313.
11. Lipartiti M, Franceschini D, Zanoni R, Gusella M, Giusti P, Cagnoli CM, Kharlamov A, Manev H: Neuroprotective effects of melatonin. Adv Exp Med Biol 1996;398:315-321.
12. Morgan PJ, Barrett P, Howell HE, Helliwell R: Melatonin receptors: Localization, molecular pharmacology and physiological significance. Neurochem Int 1994;24:101-146.
13. Ebisawa T, Karne S, Lerner MR, Reppert SM: Expression cloning of a high-affinity melatonin receptor from Xenopus dermal melano-phores. Proc Natl Acad Sci USA 1994;91:6133-6137.
14. Reppert SM, Weaver DR, Ebisawa T: Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron 1994;13: 1177-1185.
15. Reppert SM, Godson C, Mahle CD, Weaver DR, Slaugenhaupt SA, Gu-sella JF: Molecular characterization of a second melatonin receptor expressed in human retina and brain: The Mel1b melatonin receptor. Proc Natl Acad Sci USA 1995;92:8734-8738.
16. Mazzucchelli C, Pannacci M, Non-no R, Lucini V, Fraschini F, Stankov BM: The melatonin receptor in the human brain: Cloning experiments and distribution studies. Mol Brain Res 1996;39:117-126.
17. Takaki KS, Mahle CD, Watson AJ: Melatonergic ligands: Pharmaceutical development and clinical applications. Curr Pharm Des 1997;3: 429-438.
18. Sugden D, Chong NWS, Lewis DFV: Structural requirements at the melatonin receptor. Br J Pharmacol 1995;114:618-623.
19. Duranti E, Stankov B, Spadoni G, Duranti A, Lucini V, Capsoni S, Biella G, Fraschini F: 2-Bromomela-tonin: Synthesis and characterization of a potent melatonin agonist. Life Sci 1992;51:479-485.
20. Spadoni G, Stankov B, Duranti A, Biella G, Lucini V, Salvatori A, Fraschini F: 2-Substituted 5-me-thoxy-N-acyltryptamines: Synthesis, binding affinity for the melatonin receptor, and evaluation of the biological activity. J Med Chem 1993;36:4069-4074.
21. Mor M, Rivara S, Silva C, Bordi F, Plazzi PV, Spadoni G, Diamantini G, Balsamini C, Tarzia G, Fraschini F, Lucini V, Nonno R, Stankov BM: Melatonin receptor ligands: Synthesis of new melatonin derivatives and comprehensive CoMFA study. J Med Chem 1998;41:3831-3844.
22. Heward CB, Hadley MacE: Structure-activity relations of melatonin and related indolamines. Life Sci 1975;17:1167-1177.
23. 3H]dopamine release from retina. Eur J Pharmacol 1984;105:193-194.
24. Guardiola-Lemaitre B, Delagrange P: Melatonin analogues: From pharmacology to clinical application. Eur J Med Chem 1995;30:643s-651s.
25. Garratt PJ, Jones R, Rowe SJ, Sug-den D: Mapping the melatonin receptor. 1. The 5-methoxyl group of melatonin is not an essential requirement for biological activity. Bioorg Med Chem Lett 1994;4: 1555-1558.
26. Tarzia G, Diamantini G, Di Giacomo B, Spadoni G, Esposti D, Nonno R, Lucini V, Pannacci M, Fraschini F, Stankov BM: 1-(2-Alkanamido-ethyl)-6-methoxyindole derivatives: A new class of potent indole melatonin analogues. J Med Chem 1997; 40:2003-2010.
27. Jansen JM, Karlen A, Grol CJ, Hacksell U: Conformational properties of melatonin and two conformationally restricted agonists: A molecular mechanics and NMR spectroscopic study. Drug Des Discovery 1993;10:115-133.
28. Spadoni G, Balsamini C, Diaman-tini G, Di Giacomo B, Tarzia G, Mor M, Plazzi PV, Rivara S, Lucini V, Nonno R, Pannacci M, Fraschini F, Stankov BM: Conformationally restrained melatonin analogues: Synthesis, binding affinity for the melatonin receptor, evaluation of the biological activity and molecular modeling study. J Med Chem 1997; 40:1990-2002.
29. Jansen JM, Copinga S, Gruppen G, Molinari EJ, Dubocovich ML, Grol CJ: The high affinity melatonin binding site probed with conformationally restricted ligands. Pharmacophore and minireceptor models. Bioorg Med Chem 1996;4:1321-1332.
30. Grol CJ, Jansen JM: The high affinity melatonin binding site probed with conformationally restricted ligands. II. Homology modeling of the receptor. Bioorg Med Chem 1996;4: 1333-1339.
31. Sicsic S, Serraz I, Andrieux J, Bre-mont B, Mathe-Allainmat M, Pon-cet A, Shen S, Langlois M: Threedimensional quantitative structure-activity relationship of melatonin receptor ligands: A comparative molecular field analysis study. J Med Chem 1997;40:739-748.
32. Navajas C, Kokkola T, Poso A, Honka N, Gynther J, Laitinen JT: A rhodopsin-based model for melatonin recognition at its G protein-coupled receptor. Eur J Pharmacol 1996;304:173-183.
33. Garratt PJ, Vonhoff S, Rowe SJ, Sugden D: Mapping the melatonin receptor. 2. Synthesis and biological activity of indole derived melatonin analogs with restricted conformations of the C-3 amidoethane side chain. Bioorg Med Chem Lett 1994; 4:1559-1564.
34. Gruppen G, Grol CJ: Synthesis of new melatonin agonists. Proc 10th Camerino-Noordwijkerhout Symposium: Perspectives in Receptor Research, Camerino, Sept 1995.
35. Nonno R, Lucini V, Pannacci M, Mazzucchelli C, Angeloni D, Fras-chini F, Stankov BM: Pharmacological characterization of the human melatonin Mel1a receptor following stable transfection into NIH3T3 cells. Br J Pharmacol 1998;124: 485-492.
36. Cozzi B, Stankov B, Viglietti-Panzica C, Capsoni S, Aste N, Lucini V, Fraschini F, Panzica GC: Distribution and characterization of melatonin receptors in the brain of the Japanese quail, Coturnix japonica. Neurosci Lett 1993;150:149-152.